Morgan Stanley’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.5K | Sell |
13,597
-5,473
| -29% | -$6.51K | ﹤0.01% | 6857 |
|
|
2025
Q4 | $25.9K | Buy |
19,070
+14,351
| +304% | +$20.9K | ﹤0.01% | 6613 |
|
|
2025
Q3 | $7.55K | Sell |
4,719
-39,981
| -89% | -$65.1K | ﹤0.01% | 6975 |
|
|
2025
Q2 | $62.6K | Sell |
44,700
-21,058
| -32% | -$31.5K | ﹤0.01% | 6281 |
|
|
2025
Q1 | $106K | Sell |
65,758
-150,376
| -70% | -$191K | ﹤0.01% | 5985 |
|
|
2024
Q4 | $272K | Buy |
216,134
+102,443
| +90% | +$159K | ﹤0.01% | 5672 |
|
|
2024
Q3 | $214K | Buy |
113,691
+19,738
| +21% | +$78K | ﹤0.01% | 5733 |
|
|
2024
Q2 | $695K | Buy |
93,953
+23,297
| +33% | +$192K | ﹤0.01% | 5148 |
|
|
2024
Q1 | $553K | Sell |
70,656
-128,438
| -65% | -$826K | ﹤0.01% | 5270 |
|
|
2023
Q4 | $1.01M | Buy |
199,094
+150,808
| +312% | +$777K | ﹤0.01% | 5286 |
|
|
2023
Q3 | $286K | Sell |
48,286
-11,580
| -19% | -$77.1K | ﹤0.01% | 5425 |
|
|
2023
Q2 | $444K | Sell |
59,866
-40,019
| -40% | -$341K | ﹤0.01% | 5278 |
|
|
2023
Q1 | $944K | Buy |
99,885
+59,412
| +147% | +$627K | ﹤0.01% | 4897 |
|
|
2022
Q4 | $431K | Sell |
40,473
-9,699
| -19% | -$98.4K | ﹤0.01% | 5318 |
|
|
2022
Q3 | $370K | Buy |
50,172
+1,517
| +3% | +$9.43K | ﹤0.01% | 5424 |
|
|
2022
Q2 | $234K | Buy |
48,655
+28,247
| +138% | +$160K | ﹤0.01% | 5814 |
|
|
2022
Q1 | $104K | Sell |
20,408
-10,161
| -33% | -$53.5K | ﹤0.01% | 6277 |
|
|
2021
Q4 | $184K | Sell |
30,569
-13,403
| -30% | -$101K | ﹤0.01% | 6117 |
|
|
2021
Q3 | $390K | Buy |
43,972
+22,483
| +105% | +$156K | ﹤0.01% | 5643 |
|
|
2021
Q2 | $170K | Buy |
21,489
+16,900
| +368% | +$133K | ﹤0.01% | 6089 |
|
|
2021
Q1 | $35K | Buy |
4,589
+1,300
| +40% | +$11K | ﹤0.01% | 6512 |
|
|
2020
Q4 | $26K | Sell |
3,289
-30,458
| -90% | -$331K | ﹤0.01% | 6360 |
|
|
2020
Q3 | $327K | Buy |
33,747
+32,658
| +2,999% | +$360K | ﹤0.01% | 4860 |
|
|
2020
Q2 | $11K | Buy |
1,089
+568
| +109% | +$4.3K | ﹤0.01% | 6132 |
|
|
2020
Q1 | $3K | Buy |
521
+104
| +25% | +$739 | ﹤0.01% | 6309 |
|
|
2019
Q4 | $3K | Sell |
417
-43
| -9% | -$297 | ﹤0.01% | 6449 |
|
|
2019
Q3 | $3K | Hold |
460
| – | – | ﹤0.01% | 6425 |
|
|
2019
Q2 | $3K | Sell |
460
-34
| -7% | -$342 | ﹤0.01% | 6391 |
|
|
2019
Q1 | $7K | Sell |
494
-4
| -0.8% | -$64 | ﹤0.01% | 6259 |
|
|
2018
Q4 | $6K | Sell |
498
-84
| -14% | -$1.43K | ﹤0.01% | 6260 |
|
|
2018
Q3 | $12K | Buy |
582
+37
| +7% | +$753 | ﹤0.01% | 6263 |
|
|
2018
Q2 | $10K | Sell |
545
-10
| -2% | -$127 | ﹤0.01% | 6300 |
|
|
2018
Q1 | $6K | Sell |
555
-283
| -34% | -$4.81K | ﹤0.01% | 6358 |
|
|
2017
Q4 | $16K | Sell |
838
-34
| -4% | -$684 | ﹤0.01% | 6129 |
|
|
2017
Q3 | $15K | Buy |
872
+1
| +0.1% | +$22 | ﹤0.01% | 6092 |
|
|
2017
Q2 | $32K | Sell |
871
-3
| -0.3% | -$126 | ﹤0.01% | 5968 |
|
|
2017
Q1 | $40K | Sell |
874
-656
| -43% | -$25.2K | ﹤0.01% | 5895 |
|
|
2016
Q4 | $40K | Sell |
1,530
-1,394
| -48% | -$43.6K | ﹤0.01% | 5809 |
|
|
2016
Q3 | $118K | Buy |
2,924
+361
| +14% | +$18.5K | ﹤0.01% | 5240 |
|
|
2016
Q2 | $136K | Buy |
2,563
+611
| +31% | +$34.1K | ﹤0.01% | 5104 |
|
|
2016
Q1 | $117K | Sell |
1,952
-25
| -1% | -$1.58K | ﹤0.01% | 5240 |
|
|
2015
Q4 | $191K | Buy |
1,977
+544
| +38% | +$36.2K | ﹤0.01% | 5108 |
|
|
2015
Q3 | $76K | Sell |
1,433
-1,066
| -43% | -$71.2K | ﹤0.01% | 5550 |
|
|
2015
Q2 | $199K | Buy |
2,499
+798
| +47% | +$68.1K | ﹤0.01% | 5233 |
|
|
2015
Q1 | $126K | Buy |
1,701
+290
| +21% | +$34.5K | ﹤0.01% | 5430 |
|
|
2014
Q4 | $249K | Buy |
1,411
+1,201
| +572% | +$228K | ﹤0.01% | 5111 |
|
|
2014
Q3 | $42K | Buy |
210
+126
| +150% | +$25K | ﹤0.01% | 5786 |
|
|
2014
Q2 | $18K | Buy |
+84
| New | +$28K | ﹤0.01% | 6050 |
|
Other funds holding ATNM
VCM
GS
VFT
Morgan Stanley's ATNM Position: Q1 2026 in Review
Morgan Stanley reduced its Actinium Pharmaceuticals (ATNM) stake by 29% in Q1 2026, selling an estimated $6.51K and leaving 13,597 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6857.
Morgan Stanley first reported a position in ATNM in Q2 2014 and has held it in 48 quarters since. The position peaked at $1.01M in Q4 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- Morgan Stanley held 13,597 shares of Actinium Pharmaceuticals worth $13.5K as of Q1 2026.
- Morgan Stanley sold 5,473 Actinium Pharmaceuticals shares in Q1 2026, an estimated $6.51K.
- Actinium Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6857 holding.
- Morgan Stanley first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
- Morgan Stanley's Actinium Pharmaceuticals position peaked at $1.01M in Q4 2023.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.